Grifols (GRFS) Receivables - Net (2009 - 2025)
Grifols' (GRFS) quarterly Receivables - Net came in at $757.8 million in Q4 2025, up 0.59% YoY from $753.4 million in Q4 2024, and up 0.59% on a QoQ basis from $753.4 million in Q4 2024.
Grifols (GRFS) Receivables - Net (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Receivables - Net data on file, last reported at $757.8 million in Q4 2025.
- Quarterly Receivables - Net rose 0.59% year-over-year to $757.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $757.8 million (up 0.59% YoY) and the FY2025 annual result came in at $757.8 million, down 4.36% from the prior year.
- Receivables - Net advanced to $757.8 million in Q4 2025, from $753.4 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $757.8 million in Q4 2025 to a low of $496.6 million in Q4 2021.
- A 5-year average of $691.2 million and a median of $753.4 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net surged 51.82% — and 2023, when it dropped 7.94%.
- Tracing GRFS's Receivables - Net over 5 years: stood at $496.6 million in 2021, then surged by 51.82% to $754.0 million in 2022, then fell by 7.94% to $694.1 million in 2023, then gained by 8.54% to $753.4 million in 2024, then grew by 0.59% to $757.8 million in 2025.
- The last three Receivables - Net figures came in at $757.8 million (Q4 2025), $753.4 million (Q4 2024), and $694.1 million (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.66 Bn | 632.90 Bn | 17.26 Bn |
| 2 | AbbVie | 469.59 Bn | 463.02 Bn | 12.70 Bn |
| 3 | Merck | 375.61 Bn | 368.47 Bn | 12.21 Bn |
| 4 | Novartis Ag | 302.64 Bn | 294.95 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.53 Bn | 252.63 Bn | 12.86 Bn |
| 6 | Amgen | 236.78 Bn | 222.79 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 183.22 Bn | 180.04 Bn | 6.22 Bn |
| 8 | Pfizer | 160.17 Bn | 148.47 Bn | 10.94 Bn |
| 9 | Gsk | 105.95 Bn | 101.79 Bn | 8.24 Bn |
| 10 | Grifols | 5.46 Bn | 4.46 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 757.79 Mn |
| Dec 31, 2025 | 757.79 Mn |
| Dec 31, 2024 | 753.36 Mn |
| Dec 31, 2024 | 753.36 Mn |
| Dec 31, 2023 | 694.10 Mn |
| Dec 31, 2023 | 694.10 Mn |
| Dec 31, 2022 | 754.01 Mn |
| Dec 31, 2022 | 754.01 Mn |
| Dec 31, 2021 | 496.64 Mn |
| Dec 31, 2021 | 496.64 Mn |
| Dec 31, 2020 | 456.92 Mn |
| Dec 31, 2020 | 456.92 Mn |
| Dec 31, 2019 | 409.32 Mn |
| Dec 31, 2019 | 409.32 Mn |
| Dec 31, 2018 | 307.23 Mn |
| Dec 31, 2018 | 307.23 Mn |
| Jun 30, 2018 | 366.66 Mn |
| Jun 30, 2018 | 366.66 Mn |
| Dec 31, 2017 | 454.97 Mn |
| Dec 31, 2017 | 454.97 Mn |